Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Discovery of potential Toxoplasma gondii CDPK1 inhibitors with new scaffolds based on the combination of QSAR and scaffold-hopping method with in-vitro validation.

Zhang P, Jia L, Tian Y, Xi L, Duan R, Chen X, Xiao J, Yao X, Lan J, Li S.

Chem Biol Drug Des. 2019 Aug 22. doi: 10.1111/cbdd.13603. [Epub ahead of print]

PMID:
31436911
2.

Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice.

Chen J, Li ZY, Huang SY, Petersen E, Song HQ, Zhou DH, Zhu XQ.

BMC Infect Dis. 2014 Sep 6;14:487. doi: 10.1186/1471-2334-14-487.

3.

Co-administration of interleukins 7 and 15 with DNA vaccine improves protective immunity against Toxoplasma gondii.

Chen J, Li ZY, Petersen E, Liu WG, Zhu XQ.

Exp Parasitol. 2016 Mar;162:18-23. doi: 10.1016/j.exppara.2015.12.013. Epub 2015 Dec 17.

PMID:
26706605
4.

Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.

Scheele S, Geiger JA, DeRocher AE, Choi R, Smith TR, Hulverson MA, Vidadala RSR, Barrett LK, Maly DJ, Merritt EA, Ojo KK, Van Voorhis WC, Parsons M.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00051-18. doi: 10.1128/AAC.00051-18. Print 2018 Jun.

5.

Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.

Johnson SM, Murphy RC, Geiger JA, DeRocher AE, Zhang Z, Ojo KK, Larson ET, Perera BG, Dale EJ, He P, Reid MC, Fox AM, Mueller NR, Merritt EA, Fan E, Parsons M, Van Voorhis WC, Maly DJ.

J Med Chem. 2012 Mar 8;55(5):2416-26. doi: 10.1021/jm201713h. Epub 2012 Feb 27.

6.

Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.

Moine E, Dimier-Poisson I, Enguehard-Gueiffier C, Logé C, Pénichon M, Moiré N, Delehouzé C, Foll-Josselin B, Ruchaud S, Bach S, Gueiffier A, Debierre-Grockiego F, Denevault-Sabourin C.

Eur J Med Chem. 2015 Nov 13;105:80-105. doi: 10.1016/j.ejmech.2015.10.004. Epub 2015 Oct 9.

PMID:
26479029
7.

Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii.

Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera BG, Keyloun KR, Kim JE, Bhandari JG, Muller NR, Verlinde CL, White AC Jr, Merritt EA, Van Voorhis WC, Maly DJ.

ACS Med Chem Lett. 2010 Oct 14;1(7):331-335.

9.

Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.

Rutaganira FU, Barks J, Dhason MS, Wang Q, Lopez MS, Long S, Radke JB, Jones NG, Maddirala AR, Janetka JW, El Bakkouri M, Hui R, Shokat KM, Sibley LD.

J Med Chem. 2017 Dec 28;60(24):9976-9989. doi: 10.1021/acs.jmedchem.7b01192. Epub 2017 Oct 9.

10.

Design of the influenza virus inhibitors targeting the PA endonuclease using 3D-QSAR modeling, side-chain hopping, and docking.

Yan Z, Zhang L, Fu H, Wang Z, Lin J.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):539-47. doi: 10.1016/j.bmcl.2013.12.026. Epub 2013 Dec 12.

PMID:
24365156
11.

Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.

Ojo KK, Larson ET, Keyloun KR, Castaneda LJ, Derocher AE, Inampudi KK, Kim JE, Arakaki TL, Murphy RC, Zhang L, Napuli AJ, Maly DJ, Verlinde CL, Buckner FS, Parsons M, Hol WG, Merritt EA, Van Voorhis WC.

Nat Struct Mol Biol. 2010 May;17(5):602-7. doi: 10.1038/nsmb.1818. Epub 2010 May 2.

12.

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett JS, Van Voorhis WC, Maly DJ.

J Med Chem. 2016 Jul 14;59(13):6531-46. doi: 10.1021/acs.jmedchem.6b00760. Epub 2016 Jul 1.

13.

SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1.

Huang W, Ojo KK, Zhang Z, Rivas K, Vidadala RS, Scheele S, DeRocher AE, Choi R, Hulverson MA, Barrett LK, Bruzual I, Siddaramaiah LK, Kerchner KM, Kurnick MD, Freiberg GM, Kempf D, Hol WG, Merritt EA, Neckermann G, de Hostos EL, Isoherranen N, Maly DJ, Parsons M, Doggett JS, Van Voorhis WC, Fan E.

ACS Med Chem Lett. 2015 Oct 22;6(12):1184-1189. eCollection 2015 Dec 10.

14.

The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design.

Cardew EM, Verlinde CLMJ, Pohl E.

Parasitology. 2018 Feb;145(2):210-218. doi: 10.1017/S0031182017001901. Epub 2017 Dec 1. Review.

15.

Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii CDPK1 in the invasion step.

Sugi T, Kato K, Kobayashi K, Watanabe S, Kurokawa H, Gong H, Pandey K, Takemae H, Akashi H.

Eukaryot Cell. 2010 Apr;9(4):667-70. doi: 10.1128/EC.00351-09. Epub 2010 Feb 19.

16.

Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.

Lourido S, Zhang C, Lopez MS, Tang K, Barks J, Wang Q, Wildman SA, Shokat KM, Sibley LD.

J Med Chem. 2013 Apr 11;56(7):3068-77. doi: 10.1021/jm4001314. Epub 2013 Mar 26.

17.

Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents.

Zhang HB, Shen QK, Wang H, Jin C, Jin CM, Quan ZS.

Eur J Med Chem. 2018 Oct 5;158:414-427. doi: 10.1016/j.ejmech.2018.08.087. Epub 2018 Sep 1.

PMID:
30237124
18.

Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold.

Zhang Z, Ojo KK, Vidadala R, Huang W, Geiger JA, Scheele S, Choi R, Reid MC, Keyloun KR, Rivas K, Siddaramaiah LK, Comess KM, Robinson KP, Merta PJ, Kifle L, Hol WG, Parsons M, Merritt EA, Maly DJ, Verlinde CL, Van Voorhis WC, Fan E.

ACS Med Chem Lett. 2014 Jan 9;5(1):40-44.

19.

Identification of novel VP35 inhibitors: Virtual screening driven new scaffolds.

Ren JX, Zhang RT, Zhang H, Cao XS, Liu LK, Xie Y.

Biomed Pharmacother. 2016 Dec;84:199-207. doi: 10.1016/j.biopha.2016.09.034. Epub 2016 Sep 19.

PMID:
27657828
20.

Synthesis and biological evaluation of ursolic acid derivatives bearing triazole moieties as potential anti-Toxoplasma gondii agents.

Luan T, Jin C, Jin CM, Gong GH, Quan ZS.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):761-772. doi: 10.1080/14756366.2019.1584622.

Supplemental Content

Support Center